Cargando…

2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mee Kyoung, Ko, Seung-Hyun, Kim, Bo-Yeon, Kang, Eun Seok, Noh, Junghyun, Kim, Soo-Kyung, Park, Seok-O, Hur, Kyu Yeon, Chon, Suk, Moon, Min Kyong, Kim, Nan-Hee, Kim, Sang Yong, Rhee, Sang Youl, Lee, Kang-Woo, Kim, Jae Hyeon, Rhee, Eun-Jung, Chun, SungWan, Yu, Sung Hoon, Kim, Dae Jung, Kwon, Hyuk-Sang, Park, Kyong Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712226/
https://www.ncbi.nlm.nih.gov/pubmed/31441247
http://dx.doi.org/10.4093/dmj.2019.0137
Descripción
Sumario:The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.